Literature DB >> 6176493

Experimental production of Mallory bodies in mice by diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine.

H Yokoo, T R Harwood, D Racker, S Arak.   

Abstract

The first experimental production of Mallory bodies was reported by Denk et al. in 1975 in mice fed griseofulvin. We discovered a second chemical capable of producing Mallory bodies in the mouse liver in a manner similar to griseofulvin. Male Swiss albino mice were fed a powdered standard diet containing 2.5% of 3,5-diethoxycarbonyl-1,4-dihydrocollidine up to 95 days. The animals were killed at intervals and their livers were examined by light and electron microscopy. In general, the morphologic changes in the liver were similar to, but more marked than, those seen in griseofulvin-fed mice. Mallory bodies were first observed in the livers of mice killed at 40 days. In our previous experiment using griseofulvin, we first observed Mallory bodies in mice killed at 61 days. These observations suggest that 3,5-diethoxycarbonyl-1,4-dihydrocollidine may be more effective than griseofulvin in the production of Mallory bodies in mice.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176493

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Bile acid-induced Mallory body formation in drug-primed mouse liver.

Authors:  Peter Fickert; Michael Trauner; Andrea Fuchsbichler; Conny Stumptner; Kurt Zatloukal; Helmut Denk
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Mallory body filaments become insoluble after normal assembly into intermediate filaments.

Authors:  M S Pollanen; P Markiewicz; L Weyer; M C Goh; C Bergeron
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

3.  Keratin 8 phosphorylation regulates its transamidation and hepatocyte Mallory-Denk body formation.

Authors:  Raymond Kwan; Shinichiro Hanada; Masaru Harada; Pavel Strnad; Daniel H Li; M Bishr Omary
Journal:  FASEB J       Date:  2012-02-23       Impact factor: 5.191

4.  A cell culture system for the induction of Mallory bodies: Mallory bodies and aggresomes represent different types of inclusion bodies.

Authors:  Kiyoko Hirano; Bruno Guhl; Jürgen Roth; Martin Ziak
Journal:  Histochem Cell Biol       Date:  2009-04-18       Impact factor: 4.304

5.  Tamoxifen prevents induction of hepatic neoplasia by zeranol, an estrogenic food contaminant.

Authors:  J E Coe; K G Ishak; J M Ward; M J Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

6.  Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress.

Authors:  Shinichiro Hanada; Natasha T Snider; Elizabeth M Brunt; Paul F Hollenberg; M Bishr Omary
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

7.  Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation.

Authors:  Natasha T Snider; Sujith V W Weerasinghe; Amika Singla; Jessica M Leonard; Shinichiro Hanada; Philip C Andrews; Anna S Lok; M Bishr Omary
Journal:  J Cell Biol       Date:  2011-10-17       Impact factor: 10.539

Review 8.  Intermediate filament cytoskeleton of the liver in health and disease.

Authors:  P Strnad; C Stumptner; K Zatloukal; H Denk
Journal:  Histochem Cell Biol       Date:  2008-04-29       Impact factor: 4.304

9.  A Novel Mechanism for NF-κB-activation via IκB-aggregation: Implications for Hepatic Mallory-Denk-Body Induced Inflammation.

Authors:  Yi Liu; Michael J Trnka; Shenheng Guan; Doyoung Kwon; Do-Hyung Kim; J-J Chen; Peter A Greer; A L Burlingame; Maria Almira Correia
Journal:  Mol Cell Proteomics       Date:  2020-09-10       Impact factor: 5.911

10.  Transition between acute and chronic hepatotoxicity in mice is associated with impaired energy metabolism and induction of mitochondrial heme oxygenase-1.

Authors:  Aniket Nikam; Jay V Patankar; Carolin Lackner; Elisabeth Schöck; Dagmar Kratky; Kurt Zatloukal; Peter M Abuja
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.